Results 241 to 250 of about 126,356 (297)
Health at Older Ages: The Causes and Consequences of Declining Disability among the Elderly [PDF]
David M. Cutler +2 more
core
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The vasodilatory beta-blockers
Current Hypertension Reports, 2007Although well established in treating hypertension and cardiovascular (CV) disease, clinical trial data suggest that beta-blockers (eg, atenolol) may be less effective than other antihypertensive classes in reducing stroke and CV mortality despite similar blood pressure (BP) reductions.
Michala E, Pedersen, John R, Cockcroft
openaire +2 more sources
European Journal of Clinical Pharmacology, 1982
In a randomized, blind crossover study in 14 hypertensive patients with asthma, involving placebo and chronically administered (3 weeks) equipotent beta1-blocking doses of atenolol 100 mg once daily and metoprolol 100 mg bid, atenolol and metoprolol produced a similar fall in blood pressure.
D S, Lawrence +3 more
openaire +2 more sources
In a randomized, blind crossover study in 14 hypertensive patients with asthma, involving placebo and chronically administered (3 weeks) equipotent beta1-blocking doses of atenolol 100 mg once daily and metoprolol 100 mg bid, atenolol and metoprolol produced a similar fall in blood pressure.
D S, Lawrence +3 more
openaire +2 more sources
2015
Infantile hemangiomas (IHs) are the most common tumors in infancy. Their typical natural history is characterized by an early rapid growth in the first months of life and by a slow spontaneous involution in the first years of life. Even though spontaneous regression of IHs could suggest therapeutic abstention, systemic treatment is the therapy of ...
C. Gelmetti, R. Cavalli
openaire +4 more sources
Infantile hemangiomas (IHs) are the most common tumors in infancy. Their typical natural history is characterized by an early rapid growth in the first months of life and by a slow spontaneous involution in the first years of life. Even though spontaneous regression of IHs could suggest therapeutic abstention, systemic treatment is the therapy of ...
C. Gelmetti, R. Cavalli
openaire +4 more sources
BJOG: An International Journal of Obstetrics & Gynaecology, 1981
DRUGS that competitively antagonize the effects of catecholamines at beta-adrenoreceptors have been in clinical use since the mid-1960s.
openaire +3 more sources
DRUGS that competitively antagonize the effects of catecholamines at beta-adrenoreceptors have been in clinical use since the mid-1960s.
openaire +3 more sources
Psychiatric Services, 1984
Beta-adrenergic receptor blocking drugs, although not approved by the Food and Drug Administration for treatment of psychiatric disorders, have been used with increasing success in psychiatry. Many beta-blockers are now available, but only those that have high lipid solubility and thus readily penetrate the brain, such as propranolol and oxprenolol ...
R A, Dominguez, B J, Goldstein
openaire +2 more sources
Beta-adrenergic receptor blocking drugs, although not approved by the Food and Drug Administration for treatment of psychiatric disorders, have been used with increasing success in psychiatry. Many beta-blockers are now available, but only those that have high lipid solubility and thus readily penetrate the brain, such as propranolol and oxprenolol ...
R A, Dominguez, B J, Goldstein
openaire +2 more sources
Beta-blockers for hypertension
2007Two recent systematic reviews found first-line beta-blockers to be less effective in reducing the incidence of stroke and the combined endpoint of stroke, myocardial infarction, and death compared to all other antihypertensive drugs taken together. However, beta-blockers might be better or worse than a specific class of drugs for a particular outcome ...
C S, Wiysonge +6 more
openaire +2 more sources
Beta-blockers for hypertension
2012This review is an update of the Cochrane Review published in 2007, which assessed the role of beta-blockade as first-line therapy for hypertension.To quantify the effectiveness and safety of beta-blockers on morbidity and mortality endpoints in adults with hypertension.In December 2011 we searched the Cochrane Central Register of Controlled Trials ...
Charles Shey, Wiysonge +5 more
openaire +3 more sources